A levofloxacin-based triple therapy drug regimen counters Helicobacter pylori far more effectively than do dual therapy levofloxacin regimens.
At one-week, the triple therapy achieved a 90 percent eradication rate with no major adverse effects. The eradication rate did not increase with a longer regimen, report researchers at the University of Pittsburgh Medical Center, Pennsylvania, the Mayo Clinic Rochester, Minnesota and the Catholic University, Rome, Italy.
In an open-label study, the researchers compared the efficacy and tolerability of rabeprazole/levofloxacin dual therapies given for five, seven or 10 days and the same combination with amoxycillin added for seven days. One hundred and sixty patients with infection documented by the C-urea breath test and histology were randomised into four equal groups of 40 patients.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!